171 related articles for article (PubMed ID: 35818401)
1. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer.
Liang J; Guo R; Xuan M; Sun Q; Wu W
Int J Nanomedicine; 2022; 17():2961-2973. PubMed ID: 35818401
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
[TBL] [Abstract][Full Text] [Related]
3. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin.
Huan M; Zhang B; Teng Z; Cui H; Wang J; Liu X; Xia H; Zhou S; Mei Q
PLoS One; 2012; 7(9):e44116. PubMed ID: 23028490
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy.
Tan R; Tian D; Liu J; Wang C; Wan Y
Int J Nanomedicine; 2021; 16():4527-4544. PubMed ID: 34276212
[TBL] [Abstract][Full Text] [Related]
6. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Anti-Tumor Effect of Folate-Targeted FA-AMA-hyd-DOX Conjugate in a Xenograft Model of Human Breast Cancer.
Liao TT; Han JF; Zhang FY; Na R; Ye WL
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885691
[TBL] [Abstract][Full Text] [Related]
8. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy.
Shen Z; Wei W; Tanaka H; Kohama K; Ma G; Dobashi T; Maki Y; Wang H; Bi J; Dai S
Pharmacol Res; 2011 Oct; 64(4):410-9. PubMed ID: 21723392
[TBL] [Abstract][Full Text] [Related]
9. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.
Ye WL; Du JB; Zhang BL; Na R; Song YF; Mei QB; Zhao MG; Zhou SY
PLoS One; 2014; 9(5):e97358. PubMed ID: 24828815
[TBL] [Abstract][Full Text] [Related]
10. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
11. Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties.
Cheng L; Hu Q; Cheng L; Hu W; Xu M; Zhu Y; Zhang L; Chen D
Colloids Surf B Biointerfaces; 2015 Dec; 136():37-45. PubMed ID: 26360738
[TBL] [Abstract][Full Text] [Related]
12. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
14. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
15. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy.
Li J; Zhou Y; Li C; Wang D; Gao Y; Zhang C; Zhao L; Li Y; Liu Y; Li X
Bioconjug Chem; 2015 Jan; 26(1):110-9. PubMed ID: 25506713
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
[TBL] [Abstract][Full Text] [Related]
18. A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.
Liu S; Tian Y; Jiang S; Wang Z
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902021
[TBL] [Abstract][Full Text] [Related]
19. Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
Cheng X; Gao F; Xiang J; Jiang X; Chen J; Zhang J
Anticancer Drugs; 2011 Feb; 22(2):136-47. PubMed ID: 20966743
[TBL] [Abstract][Full Text] [Related]
20. Stepwise targeted drug delivery to liver cancer cells for enhanced therapeutic efficacy by galactose-grafted, ultra-pH-sensitive micelles.
Yan G; Wang J; Hu L; Wang X; Yang G; Fu S; Cheng X; Zhang P; Tang R
Acta Biomater; 2017 Mar; 51():363-373. PubMed ID: 28087485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
